Investigational drug · Phase 3
ABX464
Also called: Obefazimod
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ulcerative Colitis, Moderately to Severely Active Crohn Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
19
Any phase or sponsor naming "ABX464"
First trial start
2021
Dec 3, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABX464", any sponsor or status.
- Phase 212
Conditions studied
As listed on its trial records.
- Ulcerative Colitis
- Moderately to Severely Active Crohn Disease
Approved drugs for the same conditions: Crohn's disease · Ulcerative colitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "ABX464" as an intervention, largest first.
- ABTECT - MaintenancePivotal-lookingActive, not recruiting
Abivax S.A.Industry
NCT05535946 · 1,116 participants · Start Jan 16, 2023 · Primary completion Apr 28, 2026
Drug: ABX464; Placebo · For: Ulcerative Colitis
Sites: Dothan, Alabama; Litchfield Park, Arizona; Sun City, Arizona · 413 sites in all
- ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1Pivotal-lookingCompleted
Abivax S.A.Industry
NCT05507203 · 639 participants · Start Nov 16, 2022 · Primary completion Jun 24, 2025
Drug: ABX464; Placebo · For: Ulcerative Colitis
Sites: Dothan, Alabama; Guntersville, Alabama; Homewood, Alabama · 264 sites in all
- ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2Pivotal-lookingCompleted
Abivax S.A.Industry
NCT05507216 · 636 participants · Start Jan 25, 2023 · Primary completion Jun 24, 2025
Drug: ABX464; Placebo · For: Ulcerative Colitis
Sites: Birmingham, Alabama; Litchfield Park, Arizona; Little Rock, Arkansas · 262 sites in all
- ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19Pivotal-lookingTerminated
Abivax S.A.Industry
NCT04393038 · 509 participants · Start Jul 1, 2020 · Primary completion Mar 5, 2021
Drug: ABX464; Placebo · For: COVID-19
Sites: Brussels, Belgium; Ghent, Belgium; Manaus, Brazil · 30 sites in all
- Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative ColitisPivotal-lookingCompleted
Abivax S.A.Industry
NCT03760003 · 355 participants · Start Aug 13, 2019 · Primary completion Apr 1, 2021
Drug: ABX464 100 mg; ABX464 50 mg and 2 more · For: Ulcerative Colitis
Sites: San Diego, California; Decatur, Georgia; Austin, Texas · 130 sites in all
Abivax S.A.Industry
NCT04023396 · 217 participants · Start Jan 13, 2020 · Primary completion Feb 23, 2023
Drug: ABX464 · For: Ulcerative Colitis
Sites: Innsbruck, Austria; Klagenfurt, Austria; Linz, Austria · 120 sites in all
- Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisActive, not recruiting
Abivax S.A.Industry
NCT05177835 · 203 participants (planned) · Start Dec 3, 2021 · Primary completion Mar 2028
Drug: ABX464 · For: Ulcerative Colitis
Sites: Innsbruck, Austria; Vienna, Austria; Antwerp, Belgium · 46 sites in all
Abivax S.A.Industry
NCT02452242 · 70 participants · Start Jan 2015 · Primary completion Dec 2015
Drug: ABX464 · For: Human Immunodeficiency Virus Infections
Sites: Curepipe, Mauritius; Bangkok, Thailand; Chiang Mai, Thailand · 4 sites in all
Abivax S.A.Industry
NCT03813199 · 60 participants · Start Jul 4, 2019 · Primary completion Apr 27, 2021
Drug: ABX464 50mg; Matching Placebo and 2 more · For: Rheumatoid Arthritis
Sites: Brussels, Belgium; Ghent, Belgium; Leuven, Belgium · 24 sites in all
- Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464Completed
Abivax S.A.Industry
NCT05121714 · 59 participants · Start Dec 17, 2020 · Primary completion May 18, 2021
Drug: Caffeine; ABX464 and 1 more · For: Healthy
Sites: Merthyr Tydfil, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Biologic and small-molecule therapies for inflammatory bowel disease: mechanisms, comparative evidence and the emerging pipeline.
Wu L, Yang C, Wu J · Front Pharmacol 2026
- Efficacy and Safety of Advanced Therapies as Induction Therapy for Ulcerative Colitis: An Updated Systematic Review and Network Meta-Analysis.
Olivera PA, Lasa JS, Singh S, et al. · Clin Gastroenterol Hepatol 2026
- Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries.
Gupte D, Suthar NR, MacDonald JK, et al. · Paediatr Drugs 2026
- Obefazimod (ABX464) for moderate-to-severe Crohn's disease: clinical development of a novel oral therapeutic approach.
Honap S, Dignass A, Jairath V, et al. · Expert Opin Emerg Drugs 2026
- miR-124 upregulation as a new therapeutic strategy: The evolving role of obefazimod in ulcerative colitis.
Parra-Izquierdo V, Solitano V, Verstockt B · Curr Opin Pharmacol 2026
- Anti-fibrotic therapy in Crohn's disease: hype or reality-can intestinal fibrosis be targeted effectively?
Honap S, Dignass A, Jairath V, et al. · Expert Rev Gastroenterol Hepatol 2026
Also in development for Ulcerative Colitis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- DuvakitugSAR447189, TEV-48574 APhase 36 trials
Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
- ABBV-701Phase 22 trials
AbbVie · Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.